Guanidine Modifications Enhance the Anti-Herpes Simplex Virus Activity of (E, E)-4,6-bis (styryl)-pyrimidine Derivatives in vitro and in vivo.
The worldwide prevalence of herpes simplex virus (HSV) and shortage of efficient therapeutic strategies to counteract it are global concerns. In terms of treatment, the widely-utilized anti-HSV drugs such as acyclovir have serious limitations, e.g. drug resistance and side effects. Herein, we identified that the guanidine-modified (E, E)-4,6-bis (styryl)-pyrimidine (BS-pyrimidine) derivative 5d was an inhibitor of HSV and further elucidated the anti-HSV mechanisms of 5d both in vitro and in vivo. Cytopathic effect (CPE) inhibition assay, plaque assay and immunofluorescence assay were used to evaluate the anti-HSV effects of 5d in vitro. Membrane fusion assay, immunofluorescence assay, western blotting and pull-down assay were performed to explore the anti-HSV mechanisms of 5d. HSV-1 infected mouse model combined with HE staining and quantitative RT-PCR were used to study the anti-HSV effects of 5d in vivo. The guanidine-modified compound 5d rather than the non-modified 3a effectively inhibited both HSV-1 and HSV-2 multiplication in different cell lines, superior to the effects of acyclovir. 5d may block virus binding and post-binding process such as membrane fusion by targeting virus gB protein. In addition, 5d may also downregulate the cellular PI3K/Akt signaling pathway to interfere with HSV replication. 5d treatment also markedly improved survival and decreased viral titres in HSV-infected mice. Thus, the guanidine-modified BS-pyrimidine derivatives have the potential to be developed into novel anti-HSV agents targeting both virus gB protein and cellular PI3K/Akt pathway.